Sports injuries may lead to severe consequences for athletes. Many athletes suffer from injuries of skeletal muscle. While these injuries may be minor, they may be quite serious [1]. An athlete needs to train on a regular basis. An injury causes her/his time to be wasted. Similarly, if the athlete is a member of a certain team, the injury affects multiple people. Platelet-rich plasma (PRP) is a quite promising technique with significant potentials. PRP is an autologous blood product used in terms of sports medicine to treat acute and chronic tendon, ligament, and muscle injuries in over 86,000 athletes in the United States on annual basis [2]. PRP is a quite promising technique with significant potentials. It is expected to accelerate the healing process of tendon and ligament related injuries. This is particularly advantageous for athletes [3].
There are methods of treatment for sports injuries. Yet, sometimes these methods fail to fully rehabilitate the injury. There are cases that the athlete does not fully regain his previous performance after the injury. %55 of sports injuries are related to skeletal muscle. Aside from their physical effects, these injuries may result in pain of long duration. Furthermore, the injury may conclude the athlete's sports life because of its reversible consequences 1, 4. The reason why Platelet-Rich Plasma injection is such a promising treatment is because of the inadequacy of conventional methods 1.
The study of Platelet-Rich Plasma dates back to the 1970s. However, the 1990s were a turning point for PRP because it’s strong potential for the treatment of sports injuries was understood 5. In the past few years, PRP has caught great attention and it has started to be used commonly on people 2. Recent data states that there are nearly 90,000 athletes in the U.S that benefit from PRP. It is also commonly used in Europe 5, 6, 7.
1.1. Platelet-Rich Plasma (PRP)With the ability to heal injuries and regeneration, Platelet-Rich Plasma is a widespread breakthrough in the world of sports 8. Platelet-Rich Plasma (PRP) consists of platelets and growth factors that are concentrated. It may be mistaken for a regular blood clot, but there is a major distinction 9. While a regular blood clot consists of %94 red blood cells and %6 platelets, Platelet-Rich Plasma consists of %5 red blood cells and %94 platelets. Platelets are cells that play a key role in the healing process. Regarding the platelet ratio in PRP, its potential healing effect may be understood 8.
For the preparation of PRP, first, a blood sample has to be drawn. Then, to distinguish the components inside, it must be centrifuged. Centrifugation can be completed in two stages. This is a very common procedure to obtain PRP. For the final stage, the platelets are activated. Afterward, Platelet-Rich Plasma (PRP) is ready to be applied to the injured area. An important point to pay regard to is that PRP is very likely to turn into a clog. Therefore, it is crucial to arrange time correctly to obtain an accurate result 3.
PRP is considered as a very promising method in terms of healing injuries that are related to tendons and connective tissue. Thus, it is a major discovery for athletes who suffer commonly from these injuries 9. The key point of Platelet-Rich Plasma is that it allows platelets to reach the injury before other components. When the platelets reach the target, they can start the healing process by setting the growth factors free 10.
In the past decade, studies that focused on injury treatment showed the importance of growth factors. PRP is known to include some of these growth factors 8. Thegrowth factors in PRP assist the regeneration process. These growth factors are mainly Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor (TGF), Vascular Endothelial Growth Factor (VEGF) and Epithelial Growth Factor (EGF) 8. However, there are several other biological substances in PRP such as fibrin, fibronectin, and vitronectin 11, 12. When PRP reaches the target injured area, it triggers the mitogenesis and angiogenesis. Thus, rising the number of cells that are responsible for the healing 13.
The inadequate amount of studies on PRP brings along the issue of safety. Since the source of PRP is the patient's blood, It is possible to say PRP is incapable of transferring diseases. Therefore, the concern of HIV or hepatitis is invalid 13.
The risk of cancer is one of the concerns of Platelet-Rich Plasma. The idea behind this concern is the possibility of growth factors to trigger cell reproduction. Thus, PRP is rich in growth factors is regarded as a possible risk factor. However, there is no evidence that growth factors directly cause cancer. The target zone of growth factors is the membrane of the cell. Growth factors are not abnormal substances 13.
Until 2010, the World Anti-Doping Agency strictly prohibited the use of platelet related components. Platelet-Rich Plasma was also in the list of prohibited substances. The reason for that was the growth factors in PRP. High levels of growth factors in an athlete’s body were considered to be unjust. Yet, the regulation of PRP usage was lifted in 2011. The claim that PRP was a performance-enhancer was not proved 5.
Tennis Elbow is one of the disorders that can be cured with the help of a PRP application 14, 15. Also, several studies suggest the use of PRP for jumper's knee, rotator cuff, and Achilles tendon disorders. However, these assertions need further studying and need to be clinically researched. A study on Achilles tendon disorder demonstrated that when PRP is applied to patients with a chronic disorder, the treatment was unsuccessful 16. However, some studies suggest otherwise, claiming that PRP did lead to some improvements in the disease 17.
Anterior Cruciate Ligament reconstruction is one of the treatments that may benefit from PRP. Several studies questioned if PRP may help the healing process by curing tendons. The 6 months of post-operation was observed. However, no significant improvement was found 18, 19.
A Research that studied the effect of PRP on elbow tendinopathy was conducted on 100 people. It was observed that patients that were treated with PRP demonstrated substantial improvements in terms of pain and movement compared to the non-treated group 15.
A clinical trial studied the PRP effect specifically on chronic Achilles Tendinopathy. The study examined two control groups: the first group including a treatment method of PRP and eccentric training and the second group with saline injection and eccentric training. At the end of the study, the two groups showed no difference in terms of pain and function status 16. However, some studies argue the beneficial effect of PRP on Achilles Tendinopathy. For instance, in one research, surgery with PRP treatment resulted in improvements 17.
With PRP treatment, the sports injuries may be cured in a shorter period, meaning the athlete may continue her/his exercises shortly. The treatment is expected to reduce the risk of performance decrease after the injury. Also, the athlete may avoid the risk of recurrence of injury. Still, the detailed future effects of PRP are yet to be studied 3.
| [1] | Longo UG, Loppini M, Berton A, Spiezia F, Maffulli N, Denaro V. (2012). Tissue Engineered Strategies for Skeletal Muscle Injury. Stem Cells International. 2012:175038. | ||
| In article | View Article PubMed | ||
| [2] | Wasterlain AS, Braun HJ, Harris AH, Kim HJ, Dragoo JL. (2013). The Systemic Effects of Platelet-Rich Plasma Injection. Am J Sports Med. 41(1):186-93. | ||
| In article | View Article PubMed | ||
| [3] | Taylor DW, Petrera M, Hendry M, Theodoropoulos JS. (2011). MD A Systematic Review of the Use of Platelet-Rich Plasma in Sports Medicine as a New Treatment for Tendon and Ligament Injuries. Clin J Sport Med.; 21(4): 344-352. | ||
| In article | View Article PubMed | ||
| [4] | Beiner JM and Jokl P. (2001). Muscle contusion injuries: current treatment options.The Journal of the American Academy of Orthopaedic Surgeons, vol. 9, no. 4, pp. 227-237. | ||
| In article | View Article PubMed | ||
| [5] | Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. (2009). Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 37(11): 2259-2272. | ||
| In article | View Article PubMed | ||
| [6] | Anitua E, Sanchez M, Nurden AT, et al. (2006). Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A. 77(2): 285-293. | ||
| In article | View Article PubMed | ||
| [7] | Eppley BL, Woodell JE, Higgins J. (2004) Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. PlastReconstr Surg. 114(6):1502-1508. | ||
| In article | View Article PubMed | ||
| [8] | Rodrigues SV, Acharya AB, Thakur SL (2012) Platelet-rich plasma. A review. N Y State Dent J.; 78(1): 26-30. | ||
| In article | |||
| [9] | Marx RE (2004) Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg.; 62: 489-496. | ||
| In article | View Article PubMed | ||
| [10] | Creaney L, Hamilton B. (2008). Growth factor delivery methods in the management of sports injuries: the state of play. Br J Sports Med. 42(5): 314-320. | ||
| In article | View Article PubMed | ||
| [11] | Sanchez AR, Sheridan PJ, Kupp LI. (2003). Is platelet-rich plasma the perfect enhancement factor? a current review. Int J Oral Maxillofac Implants. 18:93-103. | ||
| In article | |||
| [12] | Tozum TF, Demiralp B (2003). Platelet-rich plasma: a promising innovation in dentistry. J canadian Dent assoc. 69:664- 669. | ||
| In article | |||
| [13] | Marx RE. (2001). Platelet-Rich Plasma (PRP): What Is PRP and What Is Not PRP? Implant Dent. 10(4): 225-8. | ||
| In article | View Article PubMed | ||
| [14] | Mishra A, Pavelko T. (2006) Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med.; 34: 1774-1778. | ||
| In article | View Article PubMed | ||
| [15] | Peerbooms JC, Sluimer J, Bruijn DJ, et al. (2010). Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med.; 38: 255-262. | ||
| In article | View Article PubMed | ||
| [16] | deVos RJ, Weir A, van Schie HT, et al. (2010) Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA.; 303: 144-149. | ||
| In article | View Article PubMed | ||
| [17] | Gaweda K, Tarczynska M, Krzyzanowski W. (2010). Treatment of Achilles tendinopathy with platelet-rich plasma. Int J Sports Med.; 31: 577-583. | ||
| In article | View Article PubMed | ||
| [18] | Orrego M, Larrain C, Rosales J, et al. (2008). Effects of platelet concentrate and a bone plug on the healing of hamstring tendons in a bone tunnel. Arthroscopy; 24: 1373-1380. | ||
| In article | View Article PubMed | ||
| [19] | Silva A, Sampaio R (2009). Anatomic ACL reconstruction: does the platelet-rich plasma accelerate tendon healing? Knee Surg Sports Traumatol Arthrosc.; 17: 676-682. | ||
| In article | View Article PubMed | ||
Published with license by Science and Education Publishing, Copyright © 2020 Onur ORAL, George NOMİKOS and Nikitas NOMIKOS
This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit
http://creativecommons.org/licenses/by/4.0/
| [1] | Longo UG, Loppini M, Berton A, Spiezia F, Maffulli N, Denaro V. (2012). Tissue Engineered Strategies for Skeletal Muscle Injury. Stem Cells International. 2012:175038. | ||
| In article | View Article PubMed | ||
| [2] | Wasterlain AS, Braun HJ, Harris AH, Kim HJ, Dragoo JL. (2013). The Systemic Effects of Platelet-Rich Plasma Injection. Am J Sports Med. 41(1):186-93. | ||
| In article | View Article PubMed | ||
| [3] | Taylor DW, Petrera M, Hendry M, Theodoropoulos JS. (2011). MD A Systematic Review of the Use of Platelet-Rich Plasma in Sports Medicine as a New Treatment for Tendon and Ligament Injuries. Clin J Sport Med.; 21(4): 344-352. | ||
| In article | View Article PubMed | ||
| [4] | Beiner JM and Jokl P. (2001). Muscle contusion injuries: current treatment options.The Journal of the American Academy of Orthopaedic Surgeons, vol. 9, no. 4, pp. 227-237. | ||
| In article | View Article PubMed | ||
| [5] | Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB, Rodeo SA. (2009). Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 37(11): 2259-2272. | ||
| In article | View Article PubMed | ||
| [6] | Anitua E, Sanchez M, Nurden AT, et al. (2006). Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A. 77(2): 285-293. | ||
| In article | View Article PubMed | ||
| [7] | Eppley BL, Woodell JE, Higgins J. (2004) Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. PlastReconstr Surg. 114(6):1502-1508. | ||
| In article | View Article PubMed | ||
| [8] | Rodrigues SV, Acharya AB, Thakur SL (2012) Platelet-rich plasma. A review. N Y State Dent J.; 78(1): 26-30. | ||
| In article | |||
| [9] | Marx RE (2004) Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg.; 62: 489-496. | ||
| In article | View Article PubMed | ||
| [10] | Creaney L, Hamilton B. (2008). Growth factor delivery methods in the management of sports injuries: the state of play. Br J Sports Med. 42(5): 314-320. | ||
| In article | View Article PubMed | ||
| [11] | Sanchez AR, Sheridan PJ, Kupp LI. (2003). Is platelet-rich plasma the perfect enhancement factor? a current review. Int J Oral Maxillofac Implants. 18:93-103. | ||
| In article | |||
| [12] | Tozum TF, Demiralp B (2003). Platelet-rich plasma: a promising innovation in dentistry. J canadian Dent assoc. 69:664- 669. | ||
| In article | |||
| [13] | Marx RE. (2001). Platelet-Rich Plasma (PRP): What Is PRP and What Is Not PRP? Implant Dent. 10(4): 225-8. | ||
| In article | View Article PubMed | ||
| [14] | Mishra A, Pavelko T. (2006) Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med.; 34: 1774-1778. | ||
| In article | View Article PubMed | ||
| [15] | Peerbooms JC, Sluimer J, Bruijn DJ, et al. (2010). Platelet-rich plasma versus corticosteroid injection with a 1-year follow-up. Am J Sports Med.; 38: 255-262. | ||
| In article | View Article PubMed | ||
| [16] | deVos RJ, Weir A, van Schie HT, et al. (2010) Platelet-rich plasma injection for chronic Achilles tendinopathy: a randomized controlled trial. JAMA.; 303: 144-149. | ||
| In article | View Article PubMed | ||
| [17] | Gaweda K, Tarczynska M, Krzyzanowski W. (2010). Treatment of Achilles tendinopathy with platelet-rich plasma. Int J Sports Med.; 31: 577-583. | ||
| In article | View Article PubMed | ||
| [18] | Orrego M, Larrain C, Rosales J, et al. (2008). Effects of platelet concentrate and a bone plug on the healing of hamstring tendons in a bone tunnel. Arthroscopy; 24: 1373-1380. | ||
| In article | View Article PubMed | ||
| [19] | Silva A, Sampaio R (2009). Anatomic ACL reconstruction: does the platelet-rich plasma accelerate tendon healing? Knee Surg Sports Traumatol Arthrosc.; 17: 676-682. | ||
| In article | View Article PubMed | ||